ENTRY       D02737                      Drug
NAME        Palivizumab (USAN/INN);
            Palivizumab (genetical recombination) (JAN);
            Synagis (TN)
  ABBR      PZ
PRODUCT     SYNAGIS (Swedish Orphan Biovitrum AB (publ))
REMARK      Therapeutic category: 6250
            ATC code: J06BD01
            Product: D02737<JP/US>
EFFICACY    Antiviral, Anti-RS virus humanized antibody
  DISEASE   Respiratory syncytial virus infection [DS:H00401]
  TYPE      Monoclonal antibody
TARGET      RSV F protein [KO:K19261]
STR_MAP     map07044  Antiviral agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J06 IMMUNE SERA AND IMMUNOGLOBULINS
               J06B IMMUNOGLOBULINS
                J06BD Antiviral monoclonal antibodies
                 J06BD01 Palivizumab
                  D02737  Palivizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Respiratory Tract Agents, Other
               Immunomodulators
                Palivizumab
                 D02737  Palivizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D02737  Palivizumab (USAN/INN); Palivizumab (genetical recombination) (JAN)
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               RSV F protein
                D02737  Palivizumab (USAN/INN) &lt;JP/US&gt;
            Antimicrobials abbreviations [BR:br08327]
             Antivirals
              Entry, fusion or uncoating inhibitor
               RSV F protein
                D02737  Palivizumab (USAN/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02737
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02737
DBLINKS     CAS: 188039-54-5
            PubChem: 47205815
///
